Smith, Ruben
Lund University · Skåne University Hospital
36 papers on CoChatORCID 0000-0001-7147-0112
Most cited papers
- Verified
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 1,603
- Verified
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 1,247
- Verified
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 741
- Verified
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 598
- Verified
The Pregnancy Risk Assessment Monitoring System (PRAMS): overview of design and methodology
Shulman, H. B., D’Angelo, D. V., Harrison, L., Smith, R. A., & Warner, L. (2018) · American Journal of Public Health
Maternal and Neonatal HealthcareReproductive Health and Contraception
Cited by 574
- Verified
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 496
- Verified
Discriminative Accuracy of [ 18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders
Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 472
- Verified
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 450
- Verified
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., et al. (2024) · JAMA
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 416
- Verified
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 375
- Verified
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease
Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 359
- Verified
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
Ossenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 311
- Verified
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Mattsson‐Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G., et al. (2021) · EMBO Molecular Medicine
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 261
- Verified
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
Berron, D., Vogel, J. W., Insel, P. S., Pereira, J. B., Xie, L., Wisse, L. E. M., Yushkevich, P. A., Palmqvist, S., Mattsson-Carlgren, N., Stomrud, E., et al. (2021) · Brain
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 240
- Verified
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 222
- Verified
Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease
Schöll, M., Ossenkoppele, R., Strandberg, O., Palmqvist, S., study, T. S. B., Jögi, J., Ohlsson, T., Smith, R., & Hansson, O. (2017) · Brain
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 180
- Verified
18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., et al. (2017) · EMBO Molecular Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 177
- Verified
18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 168
- Verified
Synaptic dysfunction in Huntington's disease: a new perspective
Smith, R., Brundin, P., & Li, J.-Y. (2005) · Cellular and Molecular Life Sciences
Genetic Neurodegenerative DiseasesNeuroscience and Neuropharmacology Research
Cited by 166
- Verified
Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease
Ossenkoppele, R., Lyoo, C. H., Jester-Broms, J., Sudre, C. H., Cho, H., Ryu, Y. H., Choi, J. Y., Smith, R., Strandberg, O., Palmqvist, S., et al. (2020) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 161
- Verified
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 149
- Verified
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies
Mattsson-Carlgren, N., Collij, L. E., Stomrud, E., Pichet Binette, A., Ossenkoppele, R., Smith, R., Karlsson, L., Lantero-Rodriguez, J., Snellman, A., Strandberg, O., et al. (2024) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 148
- Verified
Tau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 137
- Verified
Increased basal ganglia binding of 18F‐AV‐1451 in patients with progressive supranuclear palsy
Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., et al. (2017) · Movement Disorders
Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research
Cited by 118
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free